Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed480%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completed

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

NCT05495204
completedphase_3

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

NCT02707861
completedphase_3

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

NCT02475629
unknown

Compassionate Use of Ibalizumab for the Treatment of HIV Infection

NCT02028819
completedphase_2

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

NCT00784147

Clinical Trials (5)

Showing 5 of 5 trials
NCT05495204

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

Completed
NCT02707861Phase 3

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

Completed
NCT02475629Phase 3

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

Completed
NCT02028819

Compassionate Use of Ibalizumab for the Treatment of HIV Infection

Unknown
NCT00784147Phase 2

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5